Crofelemer has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for SBS and MVID. In October 2025, as announced, the company ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing SCLC and NSCLC trials; enrollment ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market ...
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of ...
14hon MSN
A CT hospital is expanding a program that is saving lives. Here’s how it works, why it was adopted
Use of whole blood products to save egregiously injured U.S. military combatants became a practice during wars in Iraq and ...
Positive full results from AstraZeneca’s Phase III TULIP-SC trial have shown the subcutaneous (SC) administration of Saphnelo ...
Jaguar Health (JAGX) announced that an article published December 29, 2025 in HEALTH, a bi-monthly English and Arabic healthcare magazine in the ...
StockStory.org on MSN
Q3 earnings outperformers: Novavax (NASDAQ:NVAX) and the rest of the therapeutics stocks
Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax ...
Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...
This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback